Sideroblastic anemia is a heterogeneous congenital and acquired disorder characterized by anemia and the presence of ring sideroblasts in the bone marrow. Congenital sideroblastic anemia (CSA) is a rare disease caused by mutations in genes involved in the heme biosynthesis, iron-sulfur [Fe-S] cluster biosynthesis, and mitochondrial protein synthesis. The most prevalent form of CSA is X-linked sideroblastic anemia, caused by mutations in the erythroid-specific δ-aminolevulinate synthase (ALAS2), which is the first enzyme of the heme biosynthesis pathway in erythroid cells. To date, a remarkable number of genetically undefined CSA cases remain, but a recent application of the next-generation sequencing technology has recognized novel causative genes for CSA. However, in most instances, the detailed molecular mechanisms of how defects of each gene result in the abnormal mitochondrial iron accumulation remain unclear. This review aims to cover the current understanding of the molecular pathophysiology of CSA.
Introduction
Sideroblastic anemia comprises a group of disorders that share characteristics of the presence of bone marrow ring sideroblasts, reflecting the excess mitochondrial iron deposition [1] [2] [3] [4] [5] . In adults, these syndromes are often found to be related to myelodysplastic syndrome (MDS), of which a vast majority of cases might result from a mutation in the RNA-splicing machinery component splicing factor 3b, subunit 1 (SF3B1) [6] . In addition, sideroblastic anemia occurs after exposure to certain drugs, alcohol, or zinc or with copper deficiency [1, 7] .
Typically, congenital forms of sideroblastic anemia (congenital sideroblastic anemia, CSA) are rare and constitute a diverse class of inherited disorders. Most CSA cases are clinically related to ineffective erythropoiesis and secondary iron overload. Often, anemia is the only manifestation of CSA and might be manifested prenatally, at birth, in childhood, and even adulthood, depending on the mutation pattern of the individual causative gene and, perhaps, other factors [4] . In some CSA cases, nonhematopoietic manifestations, such as neuromuscular and metabolic disorders, are also accompanied by hematological disorders. Based on the pathophysiology of the mitochondrial iron-heme metabolism, causative genes for CSA can be categorized into the following three subtypes: heme biosynthesis, iron-sulfur (Fe-S) cluster biosynthesis, and mitochondrial protein synthesis [1] [2] [3] [4] [5] . Recently, the application of the next-generation sequencing technology has recognized several causative genes for CSA. However, in most cases, the detailed molecular mechanisms of how defects of each gene results in the abnormal mitochondrial iron accumulation remain unclear. Hence, this review summarizes the recent progress in the molecular genetics, pathophysiology, and clinical features of CSA.
Genetic features and pathophysiology of CSA
As mentioned earlier, CSA is caused by the mutation in genes involved in heme biosynthesis, Fe-S cluster biosynthesis, and mitochondrial protein synthesis (Table 1) [1] [2] [3] [4] [5] . In addition, the presence of nonhematopoietic complications differentiates syndromic CSAs from nonsyndromic CSAs, depending on the kind of genes mutated (Table 1) . Later, we will describe the suggested roles of these genes in the pathophysiology of sideroblastic anemia.
termed ALAS1 and ALAS2, respectively. ALAS2 needs pyridoxal 5′-phosphate (PLP, vitamin B6) as a cofactor for its enzymatic activity [13] . However, the transcription factor GATA-1 is considered to induce the erythroid-specific expression of the ALAS2 gene [14] ; an iron-responsive element (IRE) located at the 5′-untranslated region (UTR) of ALAS2 is responsible for regulating the ALAS2 expression at the posttranscriptional level by the function of iron-responsive proteins (IRPs; explained later) [1, 5] . ALA is exported to the cytosol by the solute carrier family 25, member 38 (SLC25A38), where two molecules of ALA are condensed into the monopyrrole porphobilinogen (PBG), which is generated by PBG synthase (PBGS). Then, four PBG molecules are joined by hydroxymethylbilane synthase (HMBS) to form the first cyclic tetrapyrrole HMB, which is, then, converted to uroporphyrinogen III by uroporphyrinogen synthase (UROS). Subsequently, uroporphyrinogen III is decarboxylated by uroporphyrinogen decarboxylase (UROD) to form coproporphyrinogen III. Coproporphyrin III enters the mitochondria, where it is oxidatively decarboxylated by coproporphyrinogen oxidase (CPOX) to form protoporphyrinogen IX. Then, protoporphyrinogen IX is oxidized to protoporphyrin IX by protoporphyrinogen oxidase (PPOX). Finally, ferrous iron is inserted into protoporphyrin IX by ferrochelatase (FECH) to form heme; FECH is another rate-limiting enzyme of the heme biosynthetic pathway that ; Tf, transferrin; TfR, transferrin receptor; STEAP3, six-transmembrane epithelial antigen of the prostate 3; DMT1, divalent metal transporter 1; HSPA9, heat shock protein family A (Hsp70) member 9; GLRX5, glutaredoxin 5; ABCB7, adenosine triphosphate (ATP) binding cassette B7.
exists as a homodimer in which each subunit contains a Fe-S cluster that is necessary for the enzymatic activity [15] .
In addition, heme biosynthesis relies on the intracellular availability of iron. In erythroid cells, iron is acquired by transferrin receptor-mediated endocytosis of circulating transferrin-iron(III) (Fe 3+ ) complexes. Once internalized, transferrin-bound Fe 3+ are released, reduced to Fe 2+ by six-transmembrane epithelial antigen of the prostate 3 (STEAP3) [16] , exit the endosome through divalent metal transporter 1 (DMT1), enter the mitochondria, and, eventually, used to generate heme (Fig. 1) .
X-linked sideroblastic anemia due to ALAS2 defect
The most prevalent form of CSA is X-linked sideroblastic anemia (XLSA), which is attributed to mutations in the X-linked gene ALAS2, located at Xp11.21 [17] . Before the determination of the ALAS2 gene as a causative gene for CSA, the disease entity was known as pyridoxineresponsive anemia because of the characteristic improvement of anemia by the PLP administration [18] .
Clinically, patients with XLSA are typically males who present at various ages, usually aged < 40 years [4] ; however, late-onset XLSA cases have also been reported [19, 20] . Anemia is a hypochromic, microcytic disease with a varying degree and also accompanied by the systemic iron overload, even in XLSA cases without requiring red blood cell transfusion. In nearly half of the cases, anemia is responsive to PLP [21, 22] . In addition, mutations in the ALAS2 gene in patients with XLSA are heterogeneous and usually missense mutations of conserved amino acids that result in the loss-of-function [2] [3] [4] [5] 22] . To date, > 80 different mutations in ALAS2 have been reported in patients with XLSA [2, 4, 22] . Reportedly, missense mutations in ALAS2 are frequently observed in exons 5-11, encompassing exon 9, which contains the lysine responsible for the PLP binding [23] . Conversely, mutations in the ALAS2 regulatory region, such as the promoter [24] and intron 1 [25, 26] , have also been reported, which result in the decreased ALAS2 expression. Overall, a reduction in the ALAS2 expression level, as well as defects in catalysis, substrate, or cofactor affinity, and protein processing of ALAS2 have been implicated in the XLSA pathogenesis, and supplementation with PLP might contribute to the mitigation of these impairments.
Although patients with XLSA are predominantly males, as described above, cases of several female patients with the heterozygous ALAS2 mutation have also been reported [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Regarding the underlying molecular mechanisms, several studies have hypothesized the role of the skewed X chromosome inactivation in female heterozygous carriers, in which wild-type ALAS2-expressing hematopoietic cells were preferentially inactivated [27, 30, 31, 33] . However, some other studies have reported no evidence of the skewed X chromosome inactivation in heterozygous female carrier presenting as macrocytic sideroblastic anemia [34, 36] . In the latter case, the rare clinical phenotype of macrocytic sideroblastic anemia is attributed to the severe loss-of-function mutation in ALAS2, resulting in the intramedullary apoptosis of ALAS2-mutated erythroid precursors and enabling only wild-type erythroid cells to reach the circulation. Supporting the hypothesis, these cases were refractory by the PLP treatment, and the complete skewing toward the expression of wild-type ALAS2 mRNA was validated in peripheral reticulocytes [34] [35] [36] . As MDS cases typically exhibit macrocytic anemia [37] , it is imperative to consider the possibility of the presence of the heterozygous ALAS2 mutation in the diagnosis of MDS with ring sideroblasts [38] , especially in females with a family history of anemia and only minor dysplastic morphological changes.
Nearly half of the XLSA cases are unresponsive to PLP [21] , and the oral ALA supplementation was inadequate to improve anemia in XLSA, necessitating the exploration of novel therapeutic strategies [39] . However, evidence regarding the molecular characteristics of ring sideroblasts is scarce because of the lack of biological models. To date, several attempts, such as Alas2-knockout mice [40] , Alas2-knockout embryonic stem (ES) cells [41] , CRISPR/Cas9-based targeted disruption of the GATA-1 binding motif at intron 1 of murine Alas2 in vitro [42] and in vivo [43] , have not illustrated the emergence of ring sideroblasts that could be applied for further molecular analyses. We recently succeeded in establishing human ring sideroblasts from induced pluripotent cells (iPS) of XLSA [44] , as well as CRISPR/Cas9-based targeted disruption of ALAS2 intron 1 enhancer based on human proerythroblast cell line [45] . While it has been assumed that abnormal iron accumulation in the mitochondria may induce apoptotic death of erythroblasts by inducing oxidative stress, our results imply that ring sideroblasts exhibited accumulation of anti-apoptotic enzymes, such as HSP70 (heat shock protein 70), and concomitantly reduced level of reactive oxygen species, indicating that ring sideroblast formation might be a consequence of cytoprotective reaction [45] . Further analyses of the XLSA models would facilitate in elucidating its molecular etiology as well as establish novel therapeutic strategies.
CSA due to defects in SLC25A38
The second most prevalent nonsyndromic form of CSA is caused by the mutation in the SLC25A38 gene, which encodes an erythroid-specific protein of the inner mitochondrial membrane [22] . Assumedly, SLC25A38 is involved in the mitochondrial import of glycine, which is essential for the ALA synthesis ( Fig. 1) [46] . Hence, the molecular basis contributing to the ring sideroblast formation is similar to that of XLSA. Patients typically present at birth or early childhood as severe, transfusion-dependent microcytic anemia and iron overload (high serum ferritin and transferrin saturation), which clinically resembles thalassemia major [22, 47] . However, the patterns of mutation vary, including nonsense, frameshift, splice acceptor site, and missense mutations, and the mode of inheritance is autosomal recessive [46] [47] [48] [49] [50] . The present treatment comprises chronic blood transfusion coupled with iron chelation. In addition, hematopoietic stem cell transplantation is suggested as the only curative treatment [47] , although clinicians should be cautious to decide its indication. Recently, based on a zebrafish slc25a38 CSA model, the combination of glycine and folate administration was shown to exhibit promising results [51] ; however, its efficacy has not been validated in humans yet [52] .
CSA due to other heme biosynthesis defects
As described above, STEAP3 encodes ferrireductase that is responsible for the reduction of Fe 3+ to Fe 2+ in the endosomes of erythroblasts [16] . A study reported the human STEAP3 mutation in 3 affected siblings from nonconsanguineous parents, who exhibited severe hypochromic anemia, ring sideroblasts in the bone marrow, and gonadal dysfunction [53] . While a heterozygous mutation was inherited from the father, no mutation was observed in the mother. Perhaps, STEAP3 is an expressed quantitative trait locus (e-QTL), and the nonmutated allele was expressed at lower levels in affected children than that in their father. Concomitantly, mice lacking Steap3 has also demonstrated hypochromic anemia [54] . The presence of microcytic anemia in both human and mice by reduced ferrireductase activity suggests that heme biosynthesis may be compromised by the reduction of ferrous iron (Fe 2+ ), although it cannot be ruled out the possibility that the reduced Fe-S cluster biosynthesis may also contribute to the pathophysiology. Nevertheless, this disease has been described in only one family, warranting further analyses associated with the molecular mechanisms of the ring sideroblast formation.
CSA caused by defects of the Fe-S cluster biosynthesis
The Fe-S clusters are prevalent inorganic cofactors comprising iron and sulfur, which are used in fundamental biological processes such as energy production, DNA maintenance, gene expression regulation, and protein translation [55, 56] . Frataxin facilitates the delivery of iron transported from MFRN1 (mitoferrin-1, encoded by SLC25A37) to the Fe-S cluster assembly complex, including the scaffold protein ISCU (Fe-S cluster assembly enzyme), the mitochondrial HSP70 homolog HSPA9 [heat shock protein family A (Hsp70) member 9] and its cochaperone HSC20 (HscB mitochondrial Fe-S cluster cochaperone), and GLRX5 (Glutaredoxin 5). While the synthesized Fe-S cluster is provided to mitochondrial apoproteins, such as FECH [15] , it is also transported from the mitochondria to the cytosol by the mitochondrial transporter ABCB7 [adenosine triphosphate (ATP)-binding cassette B7] (Fig. 1 ) [57] .
Among cytosolic Fe-S proteins, IRPs function as an aconitase that require the Fe-S cluster for its enzymatic activity, whereas in the absence of the Fe-S cluster, they bind to IREs [58] . IRPs comprise two independent proteins, IRP1 and IRP2, the latter of which predominantly regulates the iron homeostasis in vivo [59] . As described above, the IRP-IRE system plays a vital role in the post-transcriptional regulation of ALAS2. Under iron deficiency conditions, the ALAS2 translation is suppressed by the binding of IRP1/IRP2 to the IRE; however, the IRPs detach from the IRE under conditions of iron sufficiency, resulting in the increased ALAS2 translation [60] . In addition, heme binds to IRP2 to induce its ubiquitination and proteasomal degradation [61] ; thus, the increased heme concentration along with erythroid differentiation induces the IRP2 degradation, presumably contributing to the enhanced ALAS2 translation.
CSA due to defects in ABCB7
XLSA with ataxia (XLSA/A) is a rare form of sideroblastic anemia inherited in an X-linked manner similar to XLSA. Based on the findings of the molecular analysis, XLSA/A is caused by mutations in the ABCB7 gene, which is located at Xp13.3 and encodes a mitochondrial transporter of the Fe-S cluster. To date, XLSA/A has been reported in 17 patients in 4 pedigrees, of which 5 were heterozygous females [22, 47] . Male hemizygous patients with XLSA/A present with mild anemia, motor delay, and evidence of spinocerebellar dysfunction, including early-onset ataxia associated with severe cerebellar hypoplasia [62, 63] . Conversely, none of the female heterozygous cases exhibited neurological symptoms [47] . Of note, the systemic iron overload has not been reported in this disease. While mutations are missense and anticipated to be loss-of-function [62] , nonsense mutations have not been reported, presumably, because the complete loss of ABCB7 would be incompatible with life, as it occurs in Abcb7-deficient mice [64] . During the impaired ABCB7 activity, iron remains trapped in the mitochondria and the levels of Fe-S cluster-dependent enzyme activities are declined in affected cells, resulting in the compromised ALAS2 translation by binding of IRPs to the IRE located in the 5′-UTR of ALAS2 mRNA. Furthermore, studies have suggested that ABCB7 may contribute to the FECH activity by direct interaction [65] , which would be reflected by elevated red blood cell PPIX in patients with XLSA/A.
CSA due to defects in GLRX5
As described earlier, GLRX5 encodes the mitochondrial protein essential for the Fe-S cluster biogenesis [66] . To date, only two CSA cases because of the GLRX5 mutation have been reported; while one case harbored a homozygous GLRX5 splicing mutation that markedly decreased mRNA and protein levels [3] , the other exhibited two compound heterozygous GLRX5 mutations [67] . Both cases presented mild anemia in the middle age, with a relatively low number of ring sideroblasts in the bone marrow and systemic iron overload [5, 67] . Regarding the pathological relationship, it has been reported that, based on the zebrafish model [68] as well as fibroblasts derived from a patient [69] , the loss of the Fe-S cluster by the GLRX5 mutation blocked the ALAS2 translation by binding of IRPs to the IRE, similar to the mechanism caused by the ABCB7 mutation.
CSA due to defects in HSPA9
HSPA9 is a component of the Fe-S cluster assembly complex, involved in its biogenesis [55, 56] . Recently, CSA caused by the HSPA9 mutation has been reported [70] . As the HSPA9 gene is located on chromosome 5q, the disease is estimated to be inherited as an autosomal recessive trait. However, most cases validated a common coding single-nucleotide polymorphism associated with lower mRNA expression in trans with a severe loss-of-function allele, resulting in the pseudo-dominant pattern of inheritance [70] . Like CSA caused by GLRX5 defects, the compromised ALAS2 translation might contribute to the pathophysiology. Intriguingly, although HSPA9 is one of the genes commonly deleted in 5q-MDS [71] , ring sideroblasts are uncommon in this subtype.
CSA due to abnormal mitochondrial protein synthesis
The mammalian mitochondrial respiratory chain comprises several subunits, some of which are encoded by the mitochondrial DNA (mtDNA) and NDUFB11 (NADH: ubiquinone oxidoreductase subunit B11); the latter encodes a non-catalytic component of complex I of the mitochondrial chain. In the final step of the heme biosynthesis, iron should be reduced (Fe 2+ ) when incorporated into PPIX by FECH [8] .
However, respiratory chain dysfunction results in the defect of the cytochrome c enzymatic activity, responsible for keeping the iron in a reduced (Fe 2+ ) state [1] , presumably accounting for the impaired heme biosynthesis and iron accumulation in the mitochondria. In addition, as indicated in secondary sideroblastic anemia associated with antibiotics chloramphenicol (an inhibitor of bacterial ribosomal translation, which is closely related to mammalian mitochondrial ribosomes structurally) [72] , mutations in genes involved in the mitochondrial ribosomal RNA metabolism, such as PUS1 (pseudouridylate synthase 1), YARS2 (tyrosyl-tRNA synthase 2), LARS2 (leucyl-tRNA synthase 2), and TRNT1 (tRNA nucleotidyl transferase 1), might also result in the global mitochondrial impairment by suppressing the translation of multiple mtDNA-encoded proteins [1, 2] .
Pearson marrow-pancreas syndrome
Pearson marrow-pancreas syndrome (PMPS) is a rare syndrome that involves different organs and systems, typically presenting with sideroblastic anemia, accompanied by metabolic acidosis, ataxia, renal failure, and endocrine pancreas dysfunction [73, 74] . PMPS is usually fatal, and patients die during infancy. In addition, anemia, often severe and macrocytic, usually detected in the first blood count, is frequently in the context of pancytopenia. Besides the emergence of ring sideroblasts, bone marrow aspiration specimens characteristically exhibit vacuolization of early erythroid and myeloid progenitors in 70-90% of cases [74] . Although PMPS is usually sporadic, individuals with PMPS might be born to mothers with milder mitochondrial phenotypes. Nearly half of all patients with PMPS can be reported to have heteroplasmy for a 4977-bp deletion in the mitochondrial genome [75] , whereas PMPS cases with rearrangements or duplication of the mtDNA have also been reported [22, 75] . Moreover, sideroblastic anemias because of single-nucleotide mutation in the mtDNA-encoded ATP6 gene (m.8969G > A) have been reported [76, 77] . The patients present variable phenotypes, including mitochondrial myopathy with lactic acidosis and ring sideroblasts (MLASA)-like phenotype [76] , as well as CSA with only milder syndromic phenotype or a complex metabolic phenotype [77] . Regarding the molecular mechanism contributing to ring sideroblast formation, each mtDNA defect would result in a deficiency of mitochondrially encoded subunits, which might cause defective heme synthesis, mitochondrial iron accumulation, and impaired protein synthesis.
CSA due to defects in PUS1 or YARS2
The correlation between CSA and the defective mitochondrial protein expression can be observed most directly by the MLASA phenotype, which results from mutations in genes encoding either of the two proteins, PUS1 and YARS2, also termed as MLASA1 and MLASA2, respectively [2, 22] . Patients with PUS1 mutation-caused MLASA typically present with lactic acidosis and mitochondrial myopathy related to the reduction in respiratory complexes I and IV [78, 79] . PUS1 functions in the pseudouridine modification of tRNAs [78] . Pseudouridine affects the structure of the tRNA and strengthens base pairing. Thus, failure of the pseudouridine modification might result in aberrant translation. However, most patients with MLASA die in childhood, and only a few survive adulthood [80, 81] . Conversely, YARS2 mutation-caused MLASA has been identified in several pedigrees [82] [83] [84] [85] [86] [87] . Perhaps, the decreased aminoacylation activity of mutant YARS2 enzyme might result in the decreased mitochondrial protein synthesis, leading to mitochondrial respiratory chain dysfunction [32] . Intriguingly, cytoplasmic vacuoles in normoblasts have been reported, which is a characteristic of PMPS [87] .
CSA due to defects in LARS2
LARS2 encodes mitochondrial leucyl-tRNA synthase, which attaches leucine to its cognate tRNA [88] . To date, two cases of sideroblastic anemia caused by the LARS2 mutation have been reported; while one reported 2 patients from different pedigrees (one exhibited homozygous mutation; p.Thr522Asn, the other exhibited compound heterozygous mutation; p.Thr629Met & c.1077delT), exhibiting premature ovarian failure and hearing loss (these symptoms compose Perrault syndrome) [89] , the other (compound heterozygous mutation; p.Ala430Val & p.Thr522Asn) exhibited hydrops, lactic acidosis, and multiorgan failure [88] . Regarding the underlying molecular mechanisms, the mutation resulted in the decreased level of complex I protein, which might explain variable phenotypes.
CSA due to defects in SLC19A2
Thiamine-responsive megaloblastic anemia (TRMA) represents sideroblastic anemia with systemic symptoms, including diabetes and deafness [90, 91] . However, the clinical manifestations can differ among cases. For example, some cases are not accompanied by diabetes, whereas others exhibit recurrent psychiatric manifestations or cardiac anomalies [92] [93] [94] . In addition, mutations in the high-affinity thiamine transporter SLC19A2 form the basis of the disorder, which is responsive to the thiamine supplementation [90, 91] . Although it remains unclear how mutations in SLC19A2 are involved in the sideroblast formation, it is anticipated that the impairment of thiaminedependent generation of succinyl-CoA, which is a substrate for ALAS, is the cause of the ring sideroblast abnormality. However, thiamine is also an essential cofactor in the de novo synthesis of ribose, which essential for protein synthesis. Nevertheless, the correlation between the TRMA and the mitochondrial protein synthesis must be experimentally validated in future studies.
CSA due to defects in TRNT1
A recent study reported a syndromic form of CSA associated with immunodeficiency, periodic fevers, and developmental delays (SIFD) [95] . SIFD is inherited with an autosomal recessive pattern and is caused by a mutation in the CCA-adding enzyme TRNT1, which is crucial for the tRNA maturation [95] . In addition, another recent study reported that the TRNT1 mutation caused a spectrum of disease ranging from a childhood-onset complex disease affecting most organs, including SIFD, hydrops, cardiomyopathy, sensorineural hearing loss, and renal dysfunction, to an adult-onset retinitis pigmentosa [96] [97] [98] . Similar to the mutation in genes involved in the mitochondrial ribosomal RNA metabolism, the TRNT1 mutation might account for the decreased mitochondrial protein synthesis, resulting in mitochondrial respiratory chain dysfunction in erythroid cells.
CSA due to defects in NDUFB11
Recently, two studies reported CSA because of the mutation in the X-linked gene NDUFB11, which encodes noncatalytic subunits of mitochondrial respiratory complex I [99, 100] . Both studies reported a common mutation of NDUFB11 (c.276_278del, pF93del), presented as sideroblastic anemia and variable symptoms, including lactic acidosis [99, 100] . Conversely, it has been reported that NDUFB11 mutations other than c.276_278del (p.F93del) do not present with anemia and are related to histiocytoid cardiomyopathy and microphthalmia with linear skin defects syndrome [99, 100] . However, the targeted introduction of p.F93del into K562 erythroleukemia cells results in a proliferation defect [100] ; the underlying molecular mechanism by which the p.F93del mutation induces sideroblastic anemia remains unclear.
Conclusions
Although CSA is a rare hematological disorder, it is imperative to detect genes mutations responsible for genetically unclassified CSA cases based on the next-generation sequencing technique. Perhaps, analyzing their function, based on model cells or animals, will further our knowledge of the mitochondrial iron and heme metabolism.
